Clinical Trials
18 trialsNCT04210115 2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03740165 2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07219459 2026-04-27
GDFATHERHCC01
CatalYm GmbH
Phase 2 Recruiting
NCT07246863 2026-04-21
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
Phase 2 Recruiting
NCT05645107 2026-04-13
EXCELL
Grifols Therapeutics LLC
Phase 3 Recruiting
NCT06888921 2026-04-01
MAIA-ovarian
Compugen Ltd
Phase 1/2 Recruiting
NCT04895358 2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03142334 2026-03-10
KEYNOTE-564
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05116189 2026-03-09
KEYNOTE-B96
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04882241 2026-03-06
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03635567 2026-02-04
KEYNOTE-826
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07237425 2025-12-04
Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma
Glonova Pharma Co., Ltd
Phase 1 Recruiting
NCT05951777 2025-09-29
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Hope Biosciences Research Foundation
Phase 2 Recruiting
NCT05933577 2025-09-24
V940-001
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05394714 2025-09-23
A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study
Medigen Biotechnology Corporation
Phase 1 Recruiting
NCT03834493 2025-07-18
KEYNOTE-641
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03834506 2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Completed